Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche Ticlid-Associated TTP Could Be 1 in 2,000-4,000 Patients - Labeling

Executive Summary

"The incidence of ticlopidine-associated [thrombotic thrombocytopenic purpura] may be as high as one case in every 2,000 to 4,000 patients exposed," new language in a boxed warning for Roche's Ticlid states.

You may also be interested in...

Roche "Revisiting" Safety Evaluation Post Posicor and Tasmar

Roche is "revisiting" its safety evaluation processes for new drugs following the worldwide withdrawal of Posicor (mibefradil) and the European suspension of Tasmar (tolcapone) in the second half of 1998, Roche CEO Franz Humer said during the firm's annual financial results meeting in Basel, Switzerland on March 30.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts